Search
for
Sort by
Research 451–480 of 519
- Dermatolojik Problemler ve COVID-19
- Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
- 67 Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
- P88 Real-world evidence on efficacy and safety of Janus Kinase inhibitors in the treatment of moderate to severe active Ulcerative Colitis
- Current best evidence in pigmentary dermatology
- Interleukin-15 and Tumor Necrosis Factor-α in Iraqi Patients with Alopecia Areata
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- JAK inhibition in the treatment of alopecia areata – a promising new dawn?
- Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata
- Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
- Population exposure–response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata
- Pharmacological activities of Abrus precatorius Linn.: A comprehensive review of its ethnomedicinal uses and phytochemical profile.
- Pharmacological activities of Abrus precatorius Linn.: A comprehensive review of its ethnomedicinal uses and phytochemical profile.
- Approach to Managing Recalcitrant Alopecia Areata with Combination Therapy: A Series of Five Cases in Black Pediatric Patients
- “<i>Nomen Omen</i>: The Myth of God Janus”
- INIBIDORES DA JANUS QUINASE PARA O TRATAMENTO DA ALOPECIA AREATA
- Etrasimod for alopecia areata: The scenario for a less extensive and moderate form
- Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
- Wiederbehaarung bei einem Patienten mit Alopecia universalis und Psoriasis vulgaris unter Deucravacitinib‐Therapie
- Efficacy and Safety of Ritlecitinib in Alopecia Areata: A Systematic Review and Meta-Analysis (Preprint)
- 290 Brepocitinib improves cicatricial alopecia and downregulates key T-helper biomarkers
- Treatment preferences of adults and adolescents with alopecia areata: A discrete choice experiment
- Treatment Patterns and Unmet Needs in the Management of Alopecia Areata: Results of a Physician’s Survey in the Middle East
- Overview of alopecia areata for managed care and payer stakeholders in the United States
- 056 IKZF1 and IKAROS overexpression contributes to the pathogenesis of alopecia areata
- A perspective on predictive markers of alopecia
- 865 Frontal fibrosing alopecia is associated with dysregulation of cholesterol biosynthesis pathways, fibrosis and mast cells
- Are Janus kinase (JAK) inhibitors beneficial in the treatment of androgenic alopecia?